Tingshuai Wang1, Na Wang2, Rongzhen Zhang1,2, Shaodong Huang2, Hua Qiu2, Fuli Long2, Minggang Wang3, Dewen Mao2. 1. School of Chinese Medicine, Hunan University of Traditional Chinese Medicine, Changsha, Hunan 410208, China. 2. Department of Hepatology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi 530023, China. 3. Department of Scientific Research, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi 530023, China.
Abstract
PURPOSE: Jie-Du-Hua-Yu (JDHY) granules are a traditional Chinese medicine with known therapeutic effects for the treatment of acute liver failure (ALF). This study explored the potential molecular mechanism(s) of JDHY granules in promoting liver regeneration and preventing ALF. METHODS: Rat models of ALF were constructed through administration of D-galactosamine (D-GalN) (600 mg/kg) and lipopolysaccharides (LPS) (20 μg/kg). Rats were gavaged with JDHY granules, and serum and liver samples were collected at 12 h post-D-GalN/LPS administration. The degree of liver injury was evaluated through hepatic pathology and alanine/aspartate aminotransferase (ALT/AST) activity. miRNA chips were used to detect the miRNA expression profiles of rat models. Bioinformatics analysis was used to identify the biological processes and cell signaling pathways mediating the therapeutic effects of JDHY. Real-time PCR (RT-PCR) and western blotting were used to validate the data. RESULTS: JDHY granules could effectively decrease the levels of ALT and AST, relieve D-GalN/LPS-induced liver injury, and improve hepatic function. JDHY granules were found to regulate the expression of 20 miRNAs and 19 mRNAs, which influenced 21 biological processes and 9 signaling pathways. Upon analysis of the therapeutic mechanism(s) governing the effects of JDHY granules on liver regeneration, enhanced DNA replication and an improved cholesterol metabolic ratio were identified. JDHY granules were also found to increase the expression of MCM3, CDK4, and TC, confirming the involvement of these pathways. Moreover, JDHY granules were found to promote hepatocyte mitosis and inhibit the progression of ALF. CONCLUSION: JDHY granules protect against D-GalN/LPS-induced ALF in rats by promoting liver regeneration through enhanced DNA replication and an improved cholesterol metabolic ratio.
PURPOSE: Jie-Du-Hua-Yu (JDHY) granules are a traditional Chinese medicine with known therapeutic effects for the treatment of acute liver failure (ALF). This study explored the potential molecular mechanism(s) of JDHY granules in promoting liver regeneration and preventing ALF. METHODS: Rat models of ALF were constructed through administration of D-galactosamine (D-GalN) (600 mg/kg) and lipopolysaccharides (LPS) (20 μg/kg). Rats were gavaged with JDHY granules, and serum and liver samples were collected at 12 h post-D-GalN/LPS administration. The degree of liver injury was evaluated through hepatic pathology and alanine/aspartate aminotransferase (ALT/AST) activity. miRNA chips were used to detect the miRNA expression profiles of rat models. Bioinformatics analysis was used to identify the biological processes and cell signaling pathways mediating the therapeutic effects of JDHY. Real-time PCR (RT-PCR) and western blotting were used to validate the data. RESULTS: JDHY granules could effectively decrease the levels of ALT and AST, relieve D-GalN/LPS-induced liver injury, and improve hepatic function. JDHY granules were found to regulate the expression of 20 miRNAs and 19 mRNAs, which influenced 21 biological processes and 9 signaling pathways. Upon analysis of the therapeutic mechanism(s) governing the effects of JDHY granules on liver regeneration, enhanced DNA replication and an improved cholesterol metabolic ratio were identified. JDHY granules were also found to increase the expression of MCM3, CDK4, and TC, confirming the involvement of these pathways. Moreover, JDHY granules were found to promote hepatocyte mitosis and inhibit the progression of ALF. CONCLUSION: JDHY granules protect against D-GalN/LPS-induced ALF in rats by promoting liver regeneration through enhanced DNA replication and an improved cholesterol metabolic ratio.
Authors: Guisheng Song; Amar Deep Sharma; Garrett R Roll; Raymond Ng; Andrew Y Lee; Robert H Blelloch; Niels M Frandsen; Holger Willenbring Journal: Hepatology Date: 2010-05 Impact factor: 17.425
Authors: Shahana Majid; Altaf A Dar; Sharanjot Saini; Yi Chen; Varahram Shahryari; Jan Liu; Mohd Saif Zaman; Hiroshi Hirata; Soichiro Yamamura; Koji Ueno; Yuichiro Tanaka; Rajvir Dahiya Journal: Cancer Res Date: 2010-03-23 Impact factor: 12.701
Authors: Jean S Campbell; Gretchen M Argast; Sebastian Y Yuen; Brian Hayes; Nelson Fausto Journal: Int J Biochem Cell Biol Date: 2010-08-11 Impact factor: 5.085
Authors: Constantine J Karvellas; Filipe S Cardoso; Michelle Gottfried; K Rajender Reddy; A James Hanje; Daniel Ganger; William M Lee Journal: Clin Gastroenterol Hepatol Date: 2016-06-13 Impact factor: 11.382